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INTRODUCTION
Prostaglandin E 2 (PGE 2 ) is a pro-inflammatory mediator that is produced from arachidonic acid by cyclooxygenase enzymes (COX). PGE 2 binds to four subtypes of receptors EP1, EP2, EP3, and EP4 (Narumiya et al., 1999; Kawahara et al., 2015) . The EP4 receptor has been shown to be important in PGE 2 -mediated inflammation (McCoy et al., 2002) and pain (Lin et al., 2006; St-Jacques & Ma, 2013) , and as such, has been identified as a potential drug target for the development of compounds blocking its action. The human and rat EP4 receptors have been cloned and expressed, allowing screening and discovery of compounds that preferentially bind to the EP4 receptor (Nakao et al., 2007) . Such selective blocking compounds can be used to understand the function of the receptor subtypes (Clark et al., 2008; Murase et al., 2008; Chen et al., 2010; Sutton et al., 2014; Xu et al., 2014; Parida et al., 2015) and have the potential to be clinically useful.
One compound, grapiprant (AT-001, AAT-007, CJ-023,423), has been studied for its binding affinity to the rat and human EP4 receptors (Nakao et al., 2007) and shown to have strong receptor binding with a K i of 20 AE 1 nanomolar (nM) and 13 AE 4 nM, respectively.
Grapiprant is a member of the piprant class of compounds that antagonize prostaglandin receptors recently defined by United States Adopted Names (USAN). Grapiprant is a highly selective EP4 prostaglandin PGE 2 receptor antagonist. This compound was demonstrated to have anti-inflammatory activity in rat models of acute and chronic inflammation (Nakao et al., 2007; Okumura et al., 2008) and has been studied in human clinical trials in patients with OA (see the AskAt Inc. Aichi, Japan website: products information). Given the action of grapiprant in rodents and humans, the compound was considered to have potential in the control of pain and inflammation in dogs.
In order to evaluate the potential of grapiprant for the control of pain and inflammation in dogs, it was necessary to measure the binding of the compound to the canine EP4 receptor and define the pharmacokinetics in the dog.
Grapiprant is approved as a veterinary drug by FDA for the control of pain and inflammation associated with osteoarthritis in dogs at a dose of 2 mg/kg (Rausch-Derra et al., 2016a) . Previous research has shown grapiprant to cause minimal side effects during 9-month administration to dogs at doses up to 50 mg/kg (Rausch-Derra et al., 2015) . In the recent research, pharmacokinetic comparison of oral commercial tablet and suspension formulation of grapiprant was studied (Rausch-Derra et al., 2016b) . A convenient and sensitive method to quantify grapiprant in canine plasma has been established (De Vito et al., 2016) . This paper describes the study of grapiprant binding against a cloned canine EP4 receptor. Together with pharmacokinetic data in dogs, the comparison of efficacious doses in rat models of pain and inflammation, and human clinical trials, an effective clinical dose for dogs was estimated.
MATERIALS AND METHODS

Materials
Grapiprant, grapiprant sodium salt, and d 5 -grapiprant for internal standard of bioanalysis were synthesized at Pfizer, Inc., Taketoyo, Aichi, Japan or RaQualia Pharma, Inc. All chemicals used in the study were reagent grade unless otherwise mentioned.
Dog EP4 binding assay
Stable expression of dog EP4 receptor in a human embryonic kidney 293 cell line. Dog EP4 receptor cDNA was cloned from dog kidney RNA and characterized in comparison with human EP4 receptor according to the methods described by Castleberry et al., 2001 . Dog EP4 receptor stably expressing cells were prepared with the EP4 cDNA clone and HEK293 cells (American Type Culture Collection) using lipofectamine (Invitrogen) and with G-418 (Invitrogen) selection.
Membrane preparation and assay procedure. The membrane preparation of dog EP4-expressing HEK293 cells and the binding experiments were conducted with the method described previously (Nakao et al., 2007) .
Data analysis. K d value was calculated with Scatchard plot analysis. IC 50 values were calculated using Microsoft Excel curve fit macro, and K i value was calculated from IC 50 value by the Cheng-Prusoff Equation (Cheng & Prusoff, 1973) . All values are expressed as mean AE standard error of the mean (SEM) of three independent experiments in which each point was performed in duplicate.
Binding of grapiprant to human, dog, and rat serum protein Assay procedure for serum protein binding. The serum protein binding of grapiprant was determined using an equilibrium dialysis method (Waters et al., 2008) . Fresh serum from male and female was collected from human, monkey, dog, and rat on the day of the study. Each cell was assembled by placing a prepared membrane (Spectra/Por 4, lot # 24338) between the cell halves, followed by assembling each 5-cell equilibrium dialyzer carrier. The right chamber of an equilibrium dialysis cell was filled with 1 mL of fortified serum, and the left side with 1 mL of Dulbecco's phosphate-buffered saline. After inserting stoppers in all ports, the 5-cell units were immersed in a water bath at 37°C. The drive system was set to rotate at 25 rpm. Following equilibration (5 h, previously determined), the carriers were removed from the water bath. The cell contents were transferred for analysis, and the volumes were recorded. Serum from human, dogs, and rats was fortified with grapiprant at nominal concentrations of 200 and 1000 ng/mL.
Concentration analysis for grapiprant. Single aliquots of the dialyzed serum or protein (100 lL), and buffer (100 lL) were transferred to 96-well deep-well block, and 25 lL of d 5 -grapiprant (500 ng/mL) was added as the internal standard (IS). Each sample was normalized to the same matrix by addition of equal volumes of the opposite matrix (serum or protein to buffer and buffer to serum or protein). Following acidifying samples with 175 lL of 1% acetic acid, samples were extracted using a Strata TM -X-C 33 l (10 mg) solid-phase extraction plate. The samples were eluted twice; sequentially to a clean 96-well block using 150 lL of methanol:ammonium hydroxide (95:5). The samples were dried down using nitrogen evaporation at 40°C, reconstituted in 100 lL of acetonitrile: water (50:50), and 20 lL was then injected onto the column. Grapiprant was analyzed using a PE Sciex API 3000, where grapiprant was chromatographically separated using a Phenomenex Luna 3 l C8 (2) column. Concentrations of grapiprant and d 5 -grapiprant were determined in positive ion mode using an LC/MS/MS assay.
Data analysis. Protein binding was determined by comparing the total amount of drug recovered from both chambers with starting target serum concentrations of 200 and 1000 ng/mL of grapiprant. Recovery of grapiprant was calculated using the following formula:
Recoveryð%Þ ¼ 100 Â f½ðCpe À CbÞ þ ðCb Â VbÞ=ðCps Â 1:0 mLÞg where Cpe = concentration of drug in the dialyzed serum at equilibrium, Cb = concentration of drug in the dialyzed buffer at equilibrium, Vpe = volume of the dialyzed serum, Vb = volume of the dialyzed buffer, and Cps is the initial concentration of grapiprant in fortified serum prior to equilibrium. The unbound fraction of drug (f ub ) was estimated by the equation described by Boudinot and Jusko (1984) as follows.
where Vpi = volume of serum initially (1.0 mL). Sampling. Three male Beagle dogs per group weighing 11.0-12.2 kg were fasted overnight prior to dose administration and allowed water ad libitum. Food was provided at 8 h postdose. Grapiprant was administered orally at the doses of 1, 3, or 10 mg/kg with suspension at a dosage volume of 2.5 mL/kg in 0.1% methylcellulose (MC) (4000 centipoises) (w/v). For intravenous administration, grapiprant was dissolved in 20% sulfobutylether-b-cyclodextrin (SBECD) (w/v) and injected at the dose of 1 mg/kg via the cephalic vein with an injection volume of 1 mL/kg over a period of 1 min to three male Beagle dogs. Blood samples (1-2 mL) were collected from the cephalic vein by heparinized syringe predose and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h postdose. Plasma was separated from blood following centrifugation and stored frozen at À30°C until the time of analysis.
Sample analysis. One millilitre of acetonitrile with IS (100 ng/ mL) was added to 100 lL of plasma samples. Samples were vortexed, sonicated (10 min), and centrifuged (4000 g, 5 min, 4°C). The supernatant was transferred to an injection vial and 10 lL injected onto a J'sphere 2.0 9 35 mm 4 lm ODS-L80 column (YMC Co. Ltd., Kyoto, Japan) at 40°C, and the flow rate was 0.35 mL/min (2790 HPLC system, Waters, Milford, MA, USA). The entire column effluent entered the Turbo Ionspray source (425°C, 6 L/min of air) of a Sciex API-365 triple quadrupole mass spectrometer (AB/MDS SCIEX, Toronto, Canada). Concentration of grapiprant was determined in positive ion mode using a LC/MS/MS assay.
Data analysis. Pharmacokinetic parameters were calculated using Microsoft Excel macro developed by Pfizer using modelindependent analysis. Terminal elimination half-life (t 1/2 ), area under the concentration-time curve (AUC), and oral bioavailability (F) were calculated as follows. kel = Àslope in log-linear scale t 1/2 = ln(2)/kel AUC was estimated using linear trapezoidal approximation.
Oral bioavailability, F (%) = (Dose iv 9 AUC 0-24,po )/ (Dose po 9AUC 0-24,iv ) 9 100. CL = dose/AUC C 0 was assumed time zero plasma concentration using initial two plasma concentrations by extrapolation.
Effects of grapiprant on weight-bearing deficit in the rat paw incision model Animals. Seven-week-old male Sprague Dawley rats were purchased from Charles River Japan Co. (Hino, Japan). Animals were housed in plastic cages with spread wood chips and free access to food and water (2 animals/cage). Environmental conditions were controlled at a 12-h light/ dark cycle with lights on at 07:00 a.m., ambient temperature at 23 AE 2°C, and humidity under 55 AE 15%. Prior to the experiment, animals were housed under these conditions for 4 days. The experimental procedures used in this study were approved by the RaQualia Pharma Animal Ethics Committee.
Osmotic pump implantation surgery. Rats were anesthetized with 2% isoflurane during osmotic pump implantation surgery. The osmotic pump implantation surgery was performed 24 h before paw incision surgery. The dorsal surface of the rats was shaved and prepared in a sterile manner with a 7.5% povidone-iodine solution. A 1-cm incision was made in the dorsal skin, and an osmotic pump filled with drug solution or vehicle was implanted subcutaneously. The skin was then closed with 5-0 nylon sutures. After surgery, the animals were allowed to recover in their cages.
Paw incision surgery. The paw incision surgery was performed according to the method described by Brennan et al. (1996) . Rats were anesthetized with 2% isoflurane during the surgery. The right planter was prepared in a sterile manner with a 7.5% povidone-iodine solution. A 1-cm longitudinal incision was made with a number 11 blade (Natsume Seisakusyo, Japan) through skin and fascia of the right planter aspect of the foot, starting 0.5 cm from the proximal edge of the heel and extending toward the toes. The plantaris muscle was elevated and incised longitudinally. The muscle origin and insertion remained intact. After hemostasis with gentle pressure, the skin was sutured with 2 stitches of 5-0 nylon on a No. 2 needle (Natsume Seisakusyo, Japan). After surgery, the animals were allowed to recover in their cages.
Weight-bearing test. The weight distribution on each hind paw was measured using an incapacitance tester (Linton Instrumentation, UK) (Bove et al., 2003) . Animals were habituated in the chamber for 4 days before the experiment. Rats were placed in an angled-plaxiglass chamber positioned so that each hind paw rested on a separated force plate. The force exerted by each hind paw was averaged for 3 s, and three measurements were taken and averaged. Animals without surgery distribute their weight equally on both hind paws. On the day of osmotic pump implantation surgery, rats showing equal weight distribution between left and right paw (≤10 g) were selected and randomized into four groups. Weight-bearing deficit as a pain response reached a maximum after 3-4 h of paw incision surgery. Thus, weight-bearing test was performed before and 3 and 4 h after the surgery. Dosing formulations of tested compound and dosing. Oral administration. Grapiprant was suspended in 0.5% MC solution (vehicle) at a concentration of 40 mg/mL with a mortar and a pestle to prepare a homogenous suspension. Grapiprant was then subsequently diluted in 0.5% MC solution to a concentration of 13.33 and 4.44 mg/mL. Grapiprant suspension at 400, 133.3, and 44.4 mg/kg or 0.5% MC solution was administered in a volume of 10 mL/kg body weight orally 30 min before surgery. Seven or eight rats per group were used.
Continuous subcutaneous injection. An osmotic pump (alzet â Model 2ML1) filled with grapiprant solution (15, 30, and 60 mg/mL) or vehicle (20% SBECD) was subcutaneously implanted in male SD rats (7 weeks old) 24 h before paw incision surgery. The pumping rate of the osmotic pump was 10 lL/h. Eight or nine rats per group were used.
Blood sampling for the determination of plasma concentration. For the determination of plasma concentration of grapiprant in rats, blood samples (approximately 0.3 mL) were collected from jugular veins with heparinized syringes at 4.5 h after oral administration or 24 and 48 h after osmotic pump implantation. The blood samples were stored on ice, separated from whole blood by centrifugation (3000 g, 5 min, 4°C), and then stored frozen below À30°C until the analysis for drug concentration.
Statistics. The weight-bearing deficit was calculated by the difference of weight distribution (g) between the right (surgery) and left (nonsurgery) paw. Data were presented as mean AE SEM. Statistical analysis was performed Bonferroni t-test following one-way ANOVA (SigmaPlot â 11.0, Systat Software, Inc. London, UK). Results were considered significant when P < 0.05.
RESULTS
Dog EP4 binding assay
The EP4 receptor membrane prepared from the EP4-HEK293 cells demonstrated a single affinity site for PGE 2 binding with
PGE 2 (1 nM) binding to dog recombinant EP4 receptor in a concentration-dependent manner with an IC 50 value of 35 AE 3.9 nM (mean AE SEM, N = 3) and with a K i value of 24 AE 2.7 nM (mean AE SEM, N = 3). The binding profile of grapiprant to dog EP4 receptor is shown in Fig. 1 .
Serum protein binding of grapiprant
In dog, rat, and human serum, sex differences were not seen on serum protein binding of grapiprant (data not shown). The mean percent fraction of unbound grapiprant at 200 and 1000 ng/mL for dog were 4.35 AE 0.38% and 5.01 AE 0.81%, approximately three-to fourfold higher than those of human and rats (Table 1) .
Pharmacokinetics of grapiprant following oral or intravenous administration in dogs
The plasma concentration of grapiprant in Beagle dogs following oral administration at doses of 1, 3, and 10 mg/kg rapidly increased with t max of 0.42-0.67 h, and the plasma levels of grapiprant were increased in a dose-dependent manner. AUC 0-24 values for 1, 3, and 10 mg/kg were 1800, 7600, and 3100 ngÁh/mL, respectively. The grapiprant t 1/2 values were in the range of 3.7-6.1 h, and bioavailability values (F) were 62%, 90%, and 110% at the doses if 1, 3, and 10 mg/kg, respectively (Fig. 2 , Table 2 ). The apparent increase in F% with increasing doses may be due to saturation of efflux pumps and/or enzymatic metabolism. In a recently published study (Rausch-Derra et al., 2016b), grapiprant PK parameters between tablet and suspension administration at the doses of 6 and 50 mg/kg were shown to have significant variabilities. Specifically, AUC values for the 50 mg/kg group exhibited 20-and 25-fold exposure for suspension and tablet, respectively, compared with those exhibited by the 6 mg/kg group. In that study, the same number of tablets or volume of suspension was administered to dogs, The serum protein binding of grapiprant was determined using an equilibrium dialysis method. Male and female serum samples were combined in this experiment.
regardless of body weight. The body weight range was between 7.95 and 10.35 kg. The study design presumably is close to actual veterinary or field use. In the present study, the dog PK study was conducted at 1, 3, and 10 mg/kg, and we did not observe a large variability in three dogs per dosing group. Our studies were conducted in a tightly controlled research environment, and the suspension formulation of grapiprant was administered to animals in accordance with the exact body weight. The protocol design difference and doses studied most likely account for the difference in the PK variability between the two studies.
Effects of grapiprant on weight-bearing deficit in the rat paw incision model
Rats exhibited weight-bearing deficit 3 and 4 h after the paw incision surgery. The weight-bearing deficit was significantly decreased by oral grapiprant treatment at a dose of 133.3 mg/kg at 3 and 4 h after the surgery as shown in Fig. 3 . Mean plasma concentration of grapiprant at 133.3 mg/kg at 4.5 h after administration in satellite animals (received same treatment without the pain test) was 378 ng/mL (average value, N = 2). Further, the weight-bearing deficit was significantly decreased by 150 lg/h continuous subcutaneous injection in a somewhat dose-dependent manner as shown in Fig. 4 . The plasma concentrations of grapiprant in tested rats are shown in Table 3 . Plasma concentrations of grapiprant at 24 and 28 h after osmotic pump implantation were almost the same at each dose, suggesting that plasma levels reached a steady state at 24 h after osmotic pump implantation. From these results, the efficacious plasma concentration of grapiprant for the relief of acute surgical pain in rats was estimated to be approximately 350 ng/mL.
Estimation of plasma level and dose required for control of pain in dogs
Estimation of an efficacious plasma concentration and dose in dogs can be calculated from comparative rat and dog data on serum protein binding, pharmacokinetics, and EP4 receptor binding affinity (Table 4) . Fig. 3 . Analgesic effect of grapiprant in the rat paw incision model. Grapiprant or vehicle (0.5% MC) was orally administered to male SD rats (7 weeks old) 30 min prior paw incision surgery of right-hind paw. Weight-bearing test was performed using Incapacitance tester before, 3 and 4 h after surgery. Data expressed as mean AE SEM Statistical analysis was performed by Bonferroni t-test following one-way
Grapiprant exhibited an analgesic effect with an efficacious plasma concentration of approximately 350 ng/mL achieved from oral dosing or subcutaneous infusion in the rat postsurgical acute pain model (Figs 3 and 4, Table 3 ). Grapiprant showed binding affinity for the rat recombinant EP4 receptor with a K i value of 20 AE 1 nM (Nakao et al., 2007) . In attempting to determine the dog efficacious plasma concentration, considering the species differences between rats and dogs in the K i values of EP4 receptor binding and percent of unbound fraction in the serum, efficacious C ave and AUC 0-24 values in dogs were estimated as 164 ng/mL and 3936 ngÁh/mL, respectively. (Table 4 , †, ¶ and **). The clinical dose for pain in dogs is estimated to be 1.7 mg/kg, p.o. by linear regression of two-sided AUC 0-24 values of dog pharmacokinetic study results of grapiprant ( Fig. 2 and Table 2 ).
DISCUSSION
Grapiprant is the first EP4 receptor-specific antagonist approved by FDA for control of pain and inflammation in dogs with osteoarthritis. Grapiprant demonstrates high affinity to dog EP4 receptors with the K i value of 24 nM, which was similar to that of rats (20 nM) (Nakao et al., 2007) . The binding of grapiprant to dog EP4 receptor appears to be competitive and to a single binding site on the receptor. There are several established experimental dog OA models, for example, spontaneous, surgically and enzymatic/chemically induced that could be used for the evaluation of analgesic drugs (Cook et al., 2010 and Piel et al., 2014) . The models require significant resources, and it is important to minimize the number of experimental animals used, due to animal welfare and ethical considerations. We utilized existing rat and human data to predict efficacy doses in order to assist in the selection of doses to test in clinical trials, with an aim of reducing the number of animals in studies.
In this study, a rat postsurgical pain model was used to determine a plasma level that provided pain relief and to calculate a predicted dog plasma level using parameters of protein binding and receptor binding, in concert with rat effectiveness data. It is well known that PGE2 is involved in both acute and chronic pain conditions in a variety of species (Stephen et al., 2013) . One limitation of this study is the possibility that an acute pain rat model could over-or underestimate the efficacy dose for chronic OA pain conditions. To address this point, data from humans with OA were also used. Grapiprant has been tested in Phase II human clinical trials for OA pain. From these results, it was found that grapiprant was efficacious in relief of signs and symptoms in a 4-week treatment using onceor twice-a-day dosing. The efficacy of grapiprant at 100 mg/ subject per day has been estimated to be equivalent to oral Fig. 4 . Analgesic effect of grapiprant evaluated by weight-bearing deficit in the rat paw incision model. Pain threshold was determined with degree of weight-bearing deficit of hind legs using Incapacitance tester. Rats were received continuously subcutaneous injection of grapiprant by osmotic pump. Data were expressed as mean AE SEM. Statistical analysis was performed by Bonferroni t-test following one-way ANOVA. ***P < 0.001, **P < 0.01, *P < 0.05 vs. vehicle group. N = 8-9 per group. Data expressed mean AE SD. The drug concentration was determined on animal that were tested on pain assay. N = 8-9 per group. Calculation formula: {Efficacious C ave in rats 9 (% of unbound drug fraction in rats/Binding K i in rats)} 9 (Binding K i in dogs/% of unbound drug fraction in dogs). **Calculation formula: Efficacious C ave in dogs 9 24.
naproxen 500 mg twice a day. The relationship between efficacious average concentration (C ave ) over 24 h and sustained EP4 receptor blockade was considered to be an important parameter for the human estimation (Pfizer internal communication). From Phase 1 studies, plasma exposure of grapiprant at 100 mg/subject, p.o., per day is 7110 ngÁh/mL as AUC 0-24 (data not shown), and efficacious average of concentration (C ave ) in human is calculated as 296 ng/mL. It has been reported that grapiprant showed binding affinity for the human recombinant EP4 receptor with a K i value of 13 AE 4 nM (Nakao et al., 2007) . In a similar way that the rat acute pain model was used, considering species differences between humans and dogs (K i values of EP4 receptor binding and % of unbound fraction in the serum), efficacious C ave concentration in dog is calculated as 114 ng/mL (calculation formula shown in the Table 5 legend). AUC 0-24 value in dogs is estimated as 2736 ngÁh/mL using this C ave . The predicted efficacious dose of grapiprant for chronic pain in dog calculated from these human data is shown in Table 5 . Clinical dose for chronic arthritis pain in dogs is estimated at 1.3 mg/kg, p.o. by linear regression of AUC 0-24 values of dog pharmacokinetic study results of grapiprant ( Fig. 2 and Table 2 , calculation formula shown in the Table 5 legend). It is interesting to note that the calculation from the rat acute pain model of a predicted dose of 1.7 mg/kg, p.o. is relatively close to the predicted dose of 1.3 mg/kg, p.o., based on an estimation from the human OA pain results.
In another study (Nakao et al., 2007) , it was reported that grapiprant exhibited an analgesic effect in the rat complete Freund's adjuvant-induced chronic inflammatory pain model at an oral dose of 19 mg/kg, and it was effective for up to 4 h after administration. The C ave of grapiprant was 325 ng/mL for 4 h after administration at that dose (data not shown). Furthermore, it was also reported that grapiprant exhibited an antiinflammatory effect in the rat adjuvant arthritis model at the dose of 29 mg/kg, twice a day . The C ave of grapiprant calculated from the AUC value was approximately 200 ng/mL. These results indicate that the rat efficacious C ave range on acute or chronic pain and inflammation is 200-350 ng/mL, and an estimated oral dose for the treatment of pain and inflammation in dogs is 1-1.7 mg/kg once a day.
The result of this study guided the full development of grapiprant and the doses to be tested in the pilot and field studies. Grapiprant has been studied for the control of pain and inflammation in dogs with naturally occurring OA. In the pivotal field study, conducted in support of FDA regulatory approval, grapiprant was effective at an oral dose of 2 mg/kg per day with the commercial tablet formulation (Rausch-Derra et al., 2016a) . This dose is very close to the dose that was predicted from the current study, comparing rat and dog parameters of EP4 receptor binding, serum protein binding, a suspension formulation pharmacokinetics and effectiveness. Furthermore, a similar dose was predicted when similar calculations were made using data generated from human clinical studies. 
